Todos Medical Records Records Weekly COVID PCR Test Volumes at Provista

  • CPass Neutralizing Antibody Tests See Growing Demand, Questions Of Infection-Acquired Immunity, Vaccine-Acquired Immunity, And Sustainability Of Booster Injections Emerging
  • The Company also entered into a new laboratory services agreement with a New Jersey-based medical practice for COVID PCR testing and cPass neutralizing antibody testing.

New York, NY, and Tel Aviv, ISRAELL, December 27, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Todos Medical Ltd., (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its highly automated COVID-19 neutralizing CLIA / CAP and cPass test lab, Provista Diagnostics, has seen record weekly COVID PCR test volumes for the weeks of December 13, 2021 and December 20. , 2021. COVID PCR testing volumes were primarily driven by the benchmark lab activities of a New York-based PCR testing lab that could not meet demand for testing from its location. The Company also entered into a new laboratory services agreement with a New Jersey-based medical practice for COVID PCR testing and COVID cPass neutralizing antibody testing.

“The demand for PCR testing is increasing rapidly in parts of the United States, and we expect this to continue beyond the holiday wave as individuals, schools and employers seek to create safe environments. , especially in areas with low vaccination rates, “said Gerald E. Commissiong, president and CEO of Todos Medical, the parent company of Provista Diagnostics. “Given the Biden administration’s pending ‘vaccine or test’ mandate that will place testing requirements on the 38% of the US adult population who have not yet been fully vaccinated against COVID-19, we are seeing the recent scarcity of testing combined with pending warrant creating demand for a very significant increase in long-term institutional COVID PCR testing for Provista. When you add the ability of the Omicron variant to evade vaccine or acquired immunity to infections, and the challenges of access and reliability of rapid antigen tests that noticeably give false negative results, COVID PCR tests with Fast turnaround times emerge as the most reliable and reliable source. information to find out your COVID infection status.

Mr Commissiong continued, “Also, when you combine these realities with a recent increase in interest in boosters to boost vaccine or acquired immunity to infection against Omicron, we start to see a marked increase in interest in the cPass neutralizing antibody test to monitor circulating neutralizing antibody test levels and enable patients to make rapid, data-driven decisions to get their booster shots, especially given emerging data which suggest that high neutralizing antibody titers produced from a recent booster injection are the most likely to protect an individual against Omicron infection. “

Recent data from Israel suggests neutralizing antibody titers in response to Pfizer / BioNTech committee the vaccine begins to decrease 4 months after complete vaccination, and that boosters from Comirnaty start to decrease after 10 weeks from the booster dose. A fourth shot (the “Second Booster”) was recently approved in Israel for immunocompromised and over 60s, and a study is underway to determine the durability of a Second Booster for the general population.

For more information on Provista’s parent company, Todos Medical, please visit For more information on Provista Diagnostics’ CLIA / CAP certified lab, please visit

About Todos Medical Ltd.

Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs vital diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S. medical diagnostics company Provista Diagnostics, Inc. to secure the rights to its CLIA / CAP certified lab based in Alpharetta, Georgia, which currently performs COVID PCR testing and blood of Videssa® breast cancer from Provista. test. The company’s state-of-the-art and patented Todos Biochemical Infrared Analyzes (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that deploys a comprehensive examination of the influence of cancer on the immune system, at the search for biochemical changes in mononuclear cells in blood and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos is focused on commercializing Videssa and will commercialize the TBIA tests thereafter.

Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to deal with the COVID-19 pandemic. The Joint Venture continues to develop diagnostic tests targeting 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s exclusive therapeutic candidate, Tollovir â„¢, is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to launch phase 2/3 clinical trials for inpatients and outpatients in Israel.

Todos is also developing blood tests for the early detection of neurodegenerative diseases, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test â„¢) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant reentry of the cell cycle by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos also distributes certain (COVID-19) testing materials and supplies to CLIA certified laboratories in the United States. The products cover multiple suppliers of PCR test kits, extraction kits, automation equipment and supplies, as well as COVID-19 antibody and antigen test kits.

For more information, please visit

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our clinical development programs and expected clinical trials. These forward-looking statements are based solely on management’s current expectations, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements, including risks and uncertainties associated with progress, timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to secure the additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in forward-looking statements: changes in technology and market requirements; delays or obstacles in starting our clinical trials; changes in legislation; the inability to develop and introduce new technologies, products and applications in a timely manner; the lack of validation of our technology as we progress and the lack of acceptance of our methods by the scientific community; failure to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; a higher cost of the final product than expected; loss of market share and price pressure resulting from competition; and laboratory results which do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise provided by law, Todos Medical assumes no obligation to publish revisions of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the United States Securities and Exchange Commission.

Contact Companies and Investors:

Richard galterio

To do Medical


[email protected]

Main logo

Comments are closed.